Browsing Tag
Amicus Therapeutics
1 post
BioMarin’s BMN 401 setback raises regulatory questions after ENPP1 deficiency trial meets only one endpoint
BioMarin moved the biomarker, not the rickets score. BMN 401 now tests how much regulators will accept in ultra-rare disease trials.